Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa.

J Transl Med · 2021 · PMC7819178 · PMID 33478521

Europe PMC DOI

hedged sentences

0.0480

closest p · 1.0× alpha

0.0890

boldest claim

The sentences

borderline significantP = .048actually significant

Improvement in PFS for HA-high tumors (stage 1 + 2) treated with PAG vs AG was borderline significant with an HR 0.51; 95% CI 0.26–1.00; P = .048, and improvement in PFS for C3M/PRO-C3 ratio high tumors treated with PAG vs AG provided a HR 0.40; 95% CI 0.17–0.92; P = .031 (stage 1) and a HR 0.46; 95% CI 0.21–0.98; P = .026 (stage 2).

also in 11,409 other papers

a trend towards significanceP = 0.089so close (0.05 < p ≤ 0.1)

A trend towards significance for PFS improvement was observed with PAG versus AG using the ROC cut-off: 8.8 months versus 3.4 months (log-rank P = 0.089; HR 0.45; 95% CI 0.18–1.16; P = 0.099; Figs. 2 d and 3 d).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.